Prime Medicine, Inc. (PRME) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
PRME EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PRME Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -58.1% | -4498.1% | -4342.4% |
| 2024 | 100.0% | -6787.4% | -6566.6% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export PRME earnings history in CSV or JSON format
Free sign-in required to download data
Prime Medicine, Inc. (PRME) Earnings Overview
As of May 8, 2026, Prime Medicine, Inc. (PRME) reported trailing twelve-month net income of -$198M, reflecting +18.3% year-over-year growth. The company earned $-1.12 per diluted share over the past four quarters, with a net profit margin of -4342.4%.
Looking at the long-term picture, PRME's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2019.
Prime Medicine, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BEAM (-$65M net income, -57.2% margin), CRSP (-$569M net income, -16569.8% margin), EDIT (-$160M net income), PRME has room to improve margins relative to the peer group. Compare PRME vs BEAM →
PRME Earnings vs Peers
Earnings metrics vs comparable public companies
PRME Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$201M | -2.7% | -$208M | $-1.35 | -4342.4% | -4498.1% |
| 2024 | -$196M | +1.1% | -$202M | $-1.65 | -6566.6% | -6787.4% |
| 2023 | -$198M | -62.6% | -$205M | $-2.18 | - | - |
| 2022 | -$122M | +26.3% | -$117M | $-1.46 | - | - |
| 2021 | -$165M | -4749.5% | -$84M | $-1.92 | - | - |
| 2020 | -$3M | -34.8% | $-932,000 | $-0.05 | -65.5% | -17.9% |
| 2019 | -$3M | - | -$2M | $-0.03 | - | - |
See PRME's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRME Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRME vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRME — Frequently Asked Questions
Quick answers to the most common questions about buying PRME stock.
Is PRME growing earnings?
PRME EPS is $-1.12, with earnings growth accelerating to +18.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-198M.
What are PRME's profit margins?
Prime Medicine, Inc. net margin is -4342.4%, with operating margin at -4498.1%. Below-average margins reflect competitive or cost pressures.
How consistent are PRME's earnings?
PRME earnings data spans 2019-2025. The accelerating earnings trend is +18.3% YoY. Historical data enables comparison across business cycles.